title: Memantine binding to a superficial site on NMDA receptors contributes to partial trapping.
abstract: Although many nervous system disorders are associated with N-methyl-D-aspartate (NMDA) receptor overactivation, pharmacological inhibition of NMDA receptors has typically demonstrated limited clinical value due to debilitating psychotomimetic side-effects. Memantine, however, induces far fewer behavioural side-effects than other NMDA receptor channel blockers such as ketamine, and slows the progressive cognitive decline associated with Alzheimer's disease. Memantine and ketamine inhibit NMDA receptors with similar affinity and kinetics. A prominent mechanistic difference between memantine and ketamine is the degree to which they are 'trapped' within the closed channel of NMDA receptors following removal of agonist: ketamine becomes trapped in nearly all NMDA receptors to which it was bound before agonist removal, whereas some bound memantine molecules dissociate after agonist removal, a phenomenon called partial trapping. Here we investigated the mechanism underlying partial trapping of memantine by recombinant NR1/2A NMDA receptors. We found that memantine dissociation from NR1/2A receptors after agonist removal (the process that results in partial trapping) followed an exponential time course with tau = 0.79 +/- 0.32 s. Neither membrane voltage depolarization nor maintained presence of memantine after agonist removal affected partial trapping, suggesting that partial trapping does not result from memantine escape through open channels. We tested the hypothesis that partial trapping results from binding of memantine to two sites, a superficial 'non-trapping' site and a deep 'trapping' site, which cannot be occupied simultaneously. This hypothesis was supported by the lack of ketamine binding to the superficial site, the voltage dependence of partial trapping, and the effect on partial trapping of a mutation near the deep site. The superficial binding site for memantine may, by causing partial trapping, contribute to memantine's unique therapeutic utility.
authors.affiliation: Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.
authors.forename: Shawn E
authors.initials: SE
authors.lastname: Kotermanski
authors.forename: Jesse T
authors.initials: JT
authors.lastname: Wood
authors.forename: Jon W
authors.initials: JW
authors.lastname: Johnson
mesh_terms: D019943:Amino Acid Substitution; D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive; D002460:Cell Line; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D007649:Ketamine / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008559:Memantine / Q000378:metabolism* / Q000494:pharmacology*; D008564:Membrane Potentials; D008959:Models, Neurological; D016297:Mutagenesis, Site-Directed; D018408:Patch-Clamp Techniques; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014162:Transfection
chemical_list: D018691:Excitatory Amino Acid Antagonists; D007649:Ketamine; D008559:Memantine; D016194:Receptors, N-Methyl-D-Aspartate; D011994:Recombinant Proteins; C409466:NR1 NMDA receptor
references.citation: Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33
references.pmid: 12955285
references.citation: Curr Opin Pharmacol. 2003 Feb;3(1):101-9
references.pmid: 12550750
references.citation: J Neurophysiol. 1997 Jan;77(1):309-23
references.pmid: 9120573
references.citation: J Physiol. 1997 Feb 15;499 ( Pt 1):27-46
references.pmid: 9061638
references.citation: J Pharmacol Exp Ther. 2005 Sep;314(3):961-71
references.pmid: 15901795
references.citation: J Physiol. 1998 Jan 1;506 ( Pt 1):13-32
references.pmid: 9481670
references.citation: Neuron. 2002 Jan 3;33(1):75-85
references.pmid: 11779481
references.citation: J Pharmacol Exp Ther. 1999 Jan;288(1):204-10
references.pmid: 9862772
references.citation: Biophys J. 1998 Mar;74(3):1305-19
references.pmid: 9512028
references.citation: Curr Opin Pharmacol. 2006 Feb;6(1):61-7
references.pmid: 16368266
references.citation: Neuropharmacology. 1995 Oct;34(10):1239-58
references.pmid: 8570022
references.citation: Mol Pharmacol. 2002 Mar;61(3):533-45
references.pmid: 11854433
references.citation: Pharmacol Rev. 1999 Mar;51(1):7-61
references.pmid: 10049997
references.citation: Nature. 1993 Jan 7;361(6407):31-9
references.pmid: 8421494
references.citation: J Physiol. 1995 Mar 1;483 ( Pt 2):367-84
references.pmid: 7650609
references.citation: Eur J Neurosci. 1996 Mar;8(3):446-54
references.pmid: 8963435
references.citation: J Neurosci. 1992 Nov;12(11):4427-36
references.pmid: 1432103
references.citation: J Neurosci. 2009 Mar 4;29(9):2774-9
references.pmid: 19261873
references.citation: Neuropharmacology. 2007 Nov;53(6):699-723
references.pmid: 17904591
references.citation: J Neurochem. 2003 Oct;87(1):56-65
references.pmid: 12969252
references.citation: Science. 1992 Sep 4;257(5075):1415-9
references.pmid: 1382314
references.citation: J Pharmacol Exp Ther. 2001 Jun;297(3):906-14
references.pmid: 11356910
references.citation: J Physiol. 1998 Oct 1;512 ( Pt 1):47-60
references.pmid: 9729616
references.citation: J Physiol. 1996 Mar 15;491 ( Pt 3):779-97
references.pmid: 8815211
references.citation: Neuropharmacology. 1993 Dec;32(12):1337-50
references.pmid: 8152525
references.citation: J Neurosci. 1996 Jun 1;16(11):3549-58
references.pmid: 8642401
references.citation: Trends Neurosci. 2003 Feb;26(2):81-9
references.pmid: 12536131